Judge hammers CellPro

CellPro Inc. came two steps closer last week to losing the market for its Ceprate SC Stem Cell Concentration System, as an FDA advisory panel recommended approval of rival Baxter Healthcare Corp.'s Isolex 300 Magnetic Cell Separator System, and a federal court judge granted an injunction against sales of Ceprate once Isolex is approved.

In March, a jury found that CPRO infringed two patents (the "Civin" patents, Nos. 4,714,680 and 4,965,204) covering CD34 monoclonal antibodies and purified stem

Read the full 776 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE